
SCIENTIFIC LEADERSHIP >>

Genentech's scientists are some of the most prolific in the industry and in their fields.
Positive Phase III
Results >>
Genentech has issued a press release on Phase III studies of ACTEMRA® (tocilizumab) in rheumatoid arthritis.
Roche Merger >>
View the April 14, 2009 press release announcing organizational and
leadership decisions.
Related press releases and filings
DHCP Letter for
Rituxan >>
Genentech has issued a Dear Healthcare Provider Letter for Rituxan® (rituximab) in rheumatoid arthritis.
Rituxan full prescribing information
Would you like to comment?
Join Diigo for a free account, or sign in if you are already a member.